Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients

Titre officiel

A Phase 3b, Multicentre, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects With Chronic Lymphocytic Leukemia.

Sommaire:

This is a global, Phase 3b, multicentre, open-label, single-arm study to evaluate the safety and efficacy of acalabrutinib 100 mg bid in approximately 600 participants with chronic lymphocytic leukemia (CLL). Participants will be enrolled into 3 cohorts: treatment-naive (TN), relapsed/refractory (R/R), and prior Bruton tyrosine kinase inhibitor (BTKi) therapy. Participants will remain on study treatment until completion of 48 cycles (28 days per cycle), disease progression, toxicity requiring discontinuation, withdrawal of consent, lost to follow-up, death, or study termination by the sponsor whichever occurs first. The duration of the study will be approximately 72 months from the first participant enrolled. This duration includes an estimated 24-month recruitment time and an assumed 48 cycles of study treatment (28 days per cycle); additional study time will be accrued during the follow-up period for those participants remaining on study treatment after completion of 48 cycles (the amount of time will vary by participant).

Description de l'essai

Primary Outcome:

  • Number of participants with adverse events
Secondary Outcome:
  • Objective response rate (ORR)
  • Duration of response (DOR)
  • Progression-free survival (PFS)
This is a Phase 3b, multicentre, open-label, single-arm study to evaluate the safety and efficacy of acalabrutinib 100 mg bid in approximately 600 participants with chronic lymphocytic leukemia (CLL). Participants will be enrolled into 3 cohorts: treatment-naive (TN) (minimum of 300 participants), relapsed/refractory (R/R) (approximately 200 participants), and prior bruton tyrosine kinase inhibitor (BTKi) therapy (up to 70 to 100 participants). Assessment of response and progression will be conducted by the investigator in accordance with the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2018 criteria. Overall response assessments will be based on evaluation of physical examinations, recording of symptoms, radiologic evaluations, and hematologic evaluations. Study treatment (acalabrutinib 100 mg bid) will be administered until disease progression, unacceptable toxicity, 48 cycles of study treatment, withdrawal of consent, loss to follow-up, death, or study termination by the sponsor, whichever comes first (each cycle is 28 days). In-clinic visits will occur every cycle for the first 6 cycles, and then every 3 cycles for the next 6 cycles. After 12 cycles "in-clinic visits" will occur every 6 cycles. Safety follow up visits will occur approximately 30 days from the last dose of study treatment. If a participant continues to derive benefit from treatment at the end of 48 cycles, they will continue to be provided with study treatment. This may include, but not be limited to, transition to a long-term extension trial, continuous supply in this trial (for eg in countries where regulatory approval is not obtained, or drug is not reimbursed) or switching to commercial drug as permitted by local regulations. Participants who remain in the trial after the completion of 48 cycles will be followed for disease progression, description of all subsequently administered anticancer therapies, and IWCLL indication for initiation of subsequent anticancer therapies q24w via standard practice until transition to regulatory approved off-study acalabrutinib, withdrawal of consent, lost to follow-up, death, or study termination by the sponsor. Participants who switch to off-study acalabrutinib will be considered as having completed the study and therefore will not have any additional study assessments, including the disease follow-up period. The duration of the study will be approximately 72 months from the first participant enrolled. This duration includes an estimated 24-month recruitment time and an assumed 48 cycles of study treatment (28 days per cycle).

Voir cet essai sur ClinicalTrials.gov

Intéressé(e) par cet essai?

Imprimez cette page et apportez-la chez votre médecin pour discuter de votre admissibilité à cet essai et des options de traitement. Seul votre médecin peut vous recommander pour un essai clinique.

Ressources

Société canadienne du cancer

Ces ressources sont fournies en partenariat avec Société canadienne du cancer